Thus, the reduced levels of MCP-1 in patients with SCD, while a tendency to increase during the clinical phase of AD, maybe because the SCD stage was the initial onset and the immune system could not respond in a timely manner, whereas in the disease stage, the immune system adjusted the response state. The gene discussed is CCL2; the disease is Schnyder corneal dystrophy.